C19orf35 Inhibitors
C19orf35 inhibitors are a class of chemical compounds that indirectly reduce the functional activity of the C19orf35 protein by targeting specific signaling pathways or cellular processes in which C19orf35 is implicated. Wortmannin, by inhibiting PI3K, leads to a reduction in PIP3 levels, crucial for AKT phosphorylation, a pathway that may be vital for C19orf35's activity, thus indirectly leading to its functional inhibition. SB203580 targets the p38 MAPK signaling pathway, reducing the phosphorylation of downstream targets and potentially inhibiting C19orf35's involvement in stress response and cytokine production. LY83583's inhibition of guanylate cyclase results in decreased cGMP levels, which may impede PKG activity and thus inhibit processes involving C19orf35. Go6983 and GF109203X, as PKC inhibitors, disrupt phosphorylation states of proteins involved in cell growth and differentiation, leading to the indirect inhibition of C19orf35.
Inhibitors like PD98059, SP600125, and Y-27632 target various kinases such as MEK, JNK, and ROCK, respectively, each playing a role in pathways that could regulate C19orf35 activity. PD98059 inhibits MEK, therefore preventing ERK pathway activation, which may be necessary for C19orf35 function. SP600125's inhibition of JNK activity could alter transcription factors and signaling molecules that are crucial for C19orf35's role in apoptotic pathways. Y-27632's inhibition of ROCK may affect actin cytoskeleton reorganization and cell motility, thus indirectly inhibiting C19orf35's function. U73122, by inhibiting PLC, decreases levels of IP3 and DAG, affecting calcium signaling and PKC activation, pathways that could influence C19orf35 activity. Chelerythrine, another PKC inhibitor, negatively impacts gene expression control and apoptosis. Lastly, ML7 targets MLCK, which affects cytoskeletal dynamics and cell motility, processes potentially regulated by C19orf35, leading to its indirect inhibition.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent phosphoinositide 3-kinase (PI3K) inhibitor. C19orf35 is involved in pathways regulated by PI3K. Inhibition of PI3K by wortmannin can lead to a decrease in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels, reducing AKT phosphorylation, which is crucial for cell survival signals that C19orf35 may depend upon, thereby indirectly inhibiting its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK. C19orf35 activity is modulated by the p38 MAPK signaling pathway. By inhibiting p38 MAPK, SB203580 can reduce the phosphorylation of downstream targets that are necessary for stress responses and cytokine production, processes that C19orf35 is potentially involved in, leading to its functional inhibition. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A broad-spectrum protein kinase C (PKC) inhibitor. C19orf35 is implicated in signaling pathways that are modulated by PKC. Go6983 can inhibit PKC activity, leading to altered phosphorylation states of proteins that are involved in cell growth and differentiation, which may indirectly inhibit the functional activity of C19orf35. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which is upstream of ERK in the MAPK pathway. C19orf35 is potentially regulated by the ERK pathway. PD98059 can prevent the activation of MEK, thus inhibiting the phosphorylation of ERK and downstream signaling that may be necessary for the functional activity of C19orf35, resulting in its indirect inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK). C19orf35 could be involved in apoptotic and cell survival pathways where JNK plays a key role. SP600125 inhibits JNK activity, potentially leading to the alteration of transcription factors and other signaling molecules that are crucial for processes involving C19orf35, indirectly inhibiting its function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of Rho-associated protein kinase (ROCK). C19orf35 may be associated with pathways regulated by ROCK. Y-27632 inhibits ROCK, which can lead to changes in the actin cytoskeleton and cell motility, processes that C19orf35 may influence, thereby indirectly inhibiting C19orf35's function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Another broad-spectrum PKC inhibitor. Similar to Go6983, GF109203X inhibits PKC activity and can disrupt the signaling pathways that control various cellular processes like cell cycle progression and apoptosis, processes where C19orf35 may play a role, thus leading to its indirect functional inhibition. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
A selective PKC inhibitor. By inhibiting PKC, chelerythrine can impair the signaling pathways involved in the control of gene expression and cell apoptosis, which are processes that C19orf35 may modulate, thereby indirectly inhibiting its function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
An inhibitor of myosin light chain kinase (MLCK). C19orf35 might be involved in cellular processes regulated by cytoskeletal dynamics, which are controlled by MLCK through myosin II regulatory light chain phosphorylation. By inhibiting MLCK, ML7 can disrupt cytoskeletal organization. | ||||||